Cases (n=15) Controls (n=15) P-value Age (Median) 50.69 30.37 0.14 ANC (/mm3)* <500 ≥ 500 9 (60%) 6 (40%) 2 (13.3%) 13 (86.7%) 0.05 Neutropenia duration^ ≤14 days >14 days 2 (13.3%) 13 (86.7%) 14 (93.3%) 1 (6.7%) 0.003 Absolute monocyte count# (/mm3) <120 ≥120 7 (46.7%) 8 (53.3%) 11 (73.3%) 4 (26.7%) 0.22 Steroid use in the year prior to the diagnosis of leukemia Yes No 0 15 1 (6.7%) 14 (93.3%) 1.00 DM Yes No 2 (13.3%) 13 (86.7%) 1 (6.7%) 14 (93.3%) 1.00 ITC prophylaxis^ Yes No 11 (73.3%) 4 (26.7%) 12 (86.7%) 3 (13.3%) 1.00 ITC bioavailable daily dose^ ≤200mg/day >200mg/day 11α 0 14α 0 0.25 Bacteremia prior to diagnosis of IMI^ Yes No 8 (53.3%) 7 (46.7%) 1 (6.7%) 14 (93.3%) 0.05 Fever unresponsive to 2nd line antibiotics Yes No 13 (86.7%) 2 (13.3%) 4 (26.7%) 11 (73.3%) 0.02 Cough Yes No 5 (33.3%) 10 (67.7%) 4 (26.7%) 11 (73.3%) 1.00 Length of stay Mean, days Range, days 51.8 29-88 27.2 9-65 0.01 Survival At 3 months At 12 months 14 (93.3%) 7 (46.7%) 14 (93.3%) 14 (93.3%) 0.007 * at diagnosis of leukemia ^ in admission in which IMD was diagnosed; for controls, value taken is that during admission for chemotherapy in the month ± 1 in which the IMI in the matched case was diagnosed # at diagnosis of IMD α the rest did not receive ITC

Table 4: Comparison between cases and controls.